Comorbid conditions in schizophrenia
- 1 January 2001
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Psychiatry
- Vol. 14 (1) , 17-23
- https://doi.org/10.1097/00001504-200101000-00004
Abstract
Psychiatric syndromes, including depression, obsessive-compulsive disorder, panic, and substance use disorders, co-occur with schizophrenia at significant rates. These syndromes interact with schizophrenia symptoms in clinically meaningful ways, and can be associated with adverse outcomes such as suicide, long-term disability, medication nonadherence, and frequent hospitalization. Data to inform treatment of co-occurring syndromes are largely anecdotal, and further studies are required to understand better the risks and benefits of treatment options. Weight gain and disturbances of glucose and lipid metabolism are emerging as significant medical comorbidities in patients treated with new-generation antipsychotic agents, and preventive interventions are urgently needed.Keywords
This publication has 45 references indexed in Scilit:
- Depression in Schizophrenia: Perspective in the Era of “Atypical” Antipsychotic AgentsAmerican Journal of Psychiatry, 2000
- Obesity: What Mental Health Professionals Need to KnowAmerican Journal of Psychiatry, 2000
- Clozapine, Diabetes Mellitus, Weight Gain, and Lipid Abnormalities: A Five-Year Naturalistic StudyAmerican Journal of Psychiatry, 2000
- Obsessive–compulsive disorder in schizophreniaJournal of Psychiatric Research, 2000
- Obsessive and Compulsive Symptoms in SchizophreniaJournal of Nervous & Mental Disease, 2000
- Prevalence and background factorsof depression in first admittedschizophrenic patientsActa Psychiatrica Scandinavica, 2000
- At Issue: Hierarchical Diagnosis in Chronic Schizophrenia: A Clinical Study of Co-occurring SyndromesSchizophrenia Bulletin, 2000
- Schizophrenia, substance misuse, and smokingCurrent Opinion in Psychiatry, 2000
- Weight GainJournal of Clinical Psychopharmacology, 1999
- Ziprasidone 80 mg/day and 160 mg/day in the Acute Exacerbation of Schizophrenia and Schizoaffective Disorder A 6-Week Placebo-Controlled TrialNeuropsychopharmacology, 1999